Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
Author:
Funder
Merck KGaA
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference60 articles.
1. Defining the clinical course of multiple sclerosis: the 2013 revisions;Lublin;Neurology,2014
2. Evolving concepts in the treatment of relapsing multiple sclerosis;Comi;Lancet,2017
3. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study;Fox;Neurology,2014
4. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS;Cohen;J Neurol,2013
5. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs;Miller;Curr Opin Neurol,2012
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Key Opinion Leaders’ Interviews to Inform the Future of Benefit–Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations;Drug Safety;2024-06-01
2. A novel MCGDM technique based on correlation coefficients under probabilistic hesitant fuzzy environment and its application in clinical comprehensive evaluation of orphan drugs;PLOS ONE;2024-05-06
3. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review;Frontiers in Pharmacology;2024-04-24
4. Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements;Frontiers in Drug Safety and Regulation;2023-09-06
5. Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis;Vaccines;2022-11-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3